20-MAY-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3638 270 107 65 31 9 02/06/2019 435 183
Screened at PD     1269 65 30 22 8 4      
Pre-Screened prior to PD     2365 201 73 39 21 5      
Treatment-naive     4 4 4 4 2 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     505 62 10 7 2 1      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     1891 173 140 137 130 3      
Screened at PD     1040 65 50 48 43 2      
Pre-Screened prior to PD     792 101 83 82 82 1      
Treatment-naive     4 4 4 4 2 0      
After PD on a Lung_MAP Sub-Study     55 3 3 3 3 0      
 
Sub-Study Assignments (open studies only)
S1800E     126 126 126 126 126 3      
S1900G     30 11 3 3 1 0      
S1900J     11 11 3 2 0 0      
S1900K     14 12 7 6 3 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     504 24 13 9 4 0      
Initial sub-study registrations     492 24 13 9 4 0      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 20 9 4 3 1 0 05/05/2023 282 103
Capmatinib + Osimertinib + Ramucirumab Y   10 6 3 2 0 0      
Capmatinib + Osimertinib Y   10 3 1 1 1 0      
S1900J: MET Amplification: Amivantamab-SC   88 2 2 2 1 0 0 11/19/2024 188 72
Amivantamab SC Y   2 2 2 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 8 8 6 5 3 0 08/08/2024 259 85
Tepotinib + Ramucirumab Y   6 6 5 4 3 0      
Tepotinib Y   2 2 1 1 0 0      
 

20-MAY-2025 6:10

Lung-MAP Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab 1 Randomization 28-Apr-25 241 64